cagrilintide novo nordisk with semaglutide Subcutaneous Cagrilintide, Shows Significant Weight Loss in Type 2 Diabetes Trial Novo Nordisk's stock drops despite
Novo Nordisk's stock drops despite CagriSema hitting goal of Phase III trial Clinical Trials Arena Updates in Medicine CagriSema in Adults With or Without Diabetes REDEFINE 1 & 2 Cagrilintide 2.4 mg + Semaglutide 2.4 mg once weekly 20.4% weight Instagram Novo Nordisk shares plunge after CagriSema obesity drug trial disappoints Reuters Another obesity contender just raised the stakes. Novo Nordisk's CagriSema combination delivered around 20% mean weight loss in a large trial. The formula combines semaglutide with cagrilintide, giving the body multiple appetite control
Pay in 4 interest-free payments of $5.44 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20

